IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health technologies, bringing safe and effective treatment to patients sooner. IXICO’s digital platform and Artificial Intelligence (AI) software are used by the global pharmaceutical industry to collate and interpret brain scan data from MRI and positron emission tomography (PET) scanners, as well as making sense of real world data collected using wearable biosensors. Our specialist data analytics services extract biomarkers from brain scan and wearable biosensor data to enable better patient selection, quantification of disease progression and assessment of patient outcomes. We provide technology-enabled services across all clinical trial phases as well as in post marketing surveillance, and our integrated digital platform provides a scalable and secure infrastructure to manage the standardisation, capture and analysis of regulatory compliant clinical data. Our neuroimaging and digital biomarkers are powering some of the most important clinical trials in neuroscience today, enabling our clients to design better trials and make rapid, better informed assessments of drugs safety and efficacy. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.